Key facts
- Stalicla’s last known valuation is $95.8M (Jun 2022).
- It has raised $56.7M; the latest was Later Stage VC ($2.5M) in Jun 2025.
- Notable investors include Ecole Polytechnique Federale de Lausanne, YADAY, LIFTT, SPRIM Global Investments, 4See Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Stalicla
- ·The full record, as it builds
Funding rounds
No funding rounds for Stalicla are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stalicla
Developer of an algorithm-based platform designed to identify subgroups of autism spectrum disorder patients. The company's tool identifies non-behavioral subgroups of patients with idiopathic autism spectrum disorder and corresponding first-in-class treatment candidates, enabling the healthcare industry to use robust sets of clinical signs and symptoms with big data analytics for effective and personalized treatment options.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2017
- Employees
- 26
- Website
- stalicla.com/
- Ownership
- Privately Held (backing)
Stalicla doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stalicla shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stalicla in its N-PORT filings yet. We sweep new filings monthly.